Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
about
DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response.Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses.Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation DeviceCharacterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin.Electroporation-enhanced delivery of nucleic acid vaccines.Clinical potential of electroporation for gene therapy and DNA vaccine delivery.State of play and clinical prospects of antibody gene transfer.Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.Enhanced Delivery of DNA or RNA Vaccines by Electroporation.Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.DNA vaccines onward and upward! 20 years and counting! Highlights of the DNA vaccines 2012 meeting.Adipose tissue: a new target for electroporation-enhanced DNA vaccines.A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.What is the antiallergic potential of DNA vaccination?DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response.A Review of DNA Vaccines Against Influenza
P2860
Q35655963-A50E4C11-3E5B-420C-BFE5-25155A47C4DFQ35826661-FA1ADEEE-70BE-4E83-974C-5CE1CD764135Q37530445-35B7635B-DB2D-4DC3-A308-0512796696D1Q37550619-8F13BE18-B597-420B-9C37-C2533AA01AD2Q37573037-50496C70-BA41-49F0-9061-74FA92C4C151Q38285418-63DA3E6F-80A9-4DB4-8349-E1D714A8498AQ38636510-8EFA5BB1-D0D2-4202-A552-7650B4ED2732Q38737706-8EA42250-35C8-48C1-BD5E-10E552E09EC8Q38835118-4EDCC7B5-B2A6-4C4A-A236-4B76A82DCD6AQ40420214-86FC73FB-4FDC-4EDB-BDF4-544753A07378Q41926555-C00B8D5F-C3B1-4C7C-9CDB-CFA659DD525DQ44106189-BC842BBC-60D9-414C-B27F-15A9C2C62536Q44420089-4AA40114-59EC-4F09-9D62-6E0CF1220EE5Q45874005-BE854041-AF37-4C40-B23D-FF14E04B3734Q46768300-23E55BD6-9D72-483D-AB79-8CA0AB21AD56Q48027406-95F66053-1763-4C90-B548-540664A31E20Q55493835-534CEC5D-46AB-4484-8C46-A61962EE97BBQ57094261-0C698E6F-9D28-401A-B94E-7A18CC7E3328
P2860
Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tolerability of intramuscular and intradermal delivery by CELLECTRA
@nl
Tolerability of intramuscular ...... device in healthy volunteers.
@en
type
label
Tolerability of intramuscular and intradermal delivery by CELLECTRA
@nl
Tolerability of intramuscular ...... device in healthy volunteers.
@en
prefLabel
Tolerability of intramuscular and intradermal delivery by CELLECTRA
@nl
Tolerability of intramuscular ...... device in healthy volunteers.
@en
P2093
P2860
P356
P1476
Tolerability of intramuscular ...... device in healthy volunteers.
@en
P2093
Amir S Khan
Jessica C Lee
Malissa C Diehl
Mark L Bagarazzi
Mary Giffear
Stephen E Daniels
P2860
P304
P356
10.4161/HV.24702
P577
2013-06-04T00:00:00Z